50 / 54
Pretreatment PD-L1(+) and IFN-γ(+) in NSCLC Patients May Lead to
Significant Decrease in Tumor Size With Durvalumab Monotherapy
•
Decrease in tumor size of 29.2%
(double positive)
•
Increase in tumor size of 10.8%
(double negative)